Under one in 10 people who could benefit from weight-loss injections including Wegovy can access them, caution the WHO as it issues its first guidance on the therapies.
Given in excess of 1,000,000,000 people worldwide currently living with obesity, it is advocating for increased and just availability to this class of drugs.
Per estimates, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"The latest guidance recognises that excess weight is a long-term condition that can be managed with comprehensive and continuous support," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are major barriers to universal availability to the injections that can assist patients in reducing considerable body mass, explains the body.
GLP-1 Therapy Shortage
Despite the present most optimistic case, the supply of such drugs might only reach about 100 million people – less than 10% of those who need them, as stated by the WHO.
The recommendation urges countries and companies to expand access, through measures such as licensing agreements.
The intellectual property rights on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is due to expire in a number of countries in 2026.
The Way Weight-Loss Injections Function
GLP-1 drugs imitate a body's own hormone to reduce digestion speed, suppress the appetite and enhance the sense of being full so individuals reduce food intake.
Individuals usually see weight reduction in the initial weeks of beginning the regular doses.
Studies suggests people may regain a significant portion within a year of halting the medication, because their usual hunger return.
To be carrying excess weight elevates your chance for contracting health problems, such as diabetes, cardiovascular issues, stroke, and some cancers.
Obesity concerns individuals in all nations and was linked to millions of fatalities worldwide in 2024, per the WHO.
